Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...

Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali Therapeutics Inc. (DNLI) 10-day simple moving average is 23.08. Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali ...

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...

Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Sunday, setting a price target of $95, which is approximately 48.67%... Evercore ISI ...

On Monday, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating DNL343 for amyotrophic lateral sclerosis.

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors. The biotech ...

Get Wall Street's Hottest Chart Every Morning Denali Therapeutics Inc DNLI CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference. The presentation primarily focused on the company’s ...